188 related articles for article (PubMed ID: 14968337)
1. [Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Wittlinger T; Kröger K
Herz; 2004 Feb; 29(1):12-6. PubMed ID: 14968337
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
Mohler ER; Hiatt WR; Creager MA
Circulation; 2003 Sep; 108(12):1481-6. PubMed ID: 12952839
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Corvol JC; Bouzamondo A; Sirol M; Hulot JS; Sanchez P; Lechat P
Arch Intern Med; 2003 Mar; 163(6):669-76. PubMed ID: 12639199
[TBL] [Abstract][Full Text] [Related]
4. Dyslipoproteinemia and peripheral arterial occlusive disease.
Kröger K
Angiology; 2004; 55(2):135-8. PubMed ID: 15026867
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
6. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Scheen AJ; Kulbertus H
Rev Med Liege; 2004 Mar; 59(3):167-73. PubMed ID: 15139406
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
10. The influence of atorvastatin on walking performance in peripheral arterial disease.
Bregar U; Poredos P; Sabovic M; Jug B; Sebestjen M
Vasa; 2009 May; 38(2):155-9. PubMed ID: 19588303
[TBL] [Abstract][Full Text] [Related]
11. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
12. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
14. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Hecht HS; Harman SM
Am J Cardiol; 2003 Jan; 91(1):42-5. PubMed ID: 12505569
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
18. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
Cowell SJ; Newby DE; Prescott RJ; Bloomfield P; Reid J; Northridge DB; Boon NA;
N Engl J Med; 2005 Jun; 352(23):2389-97. PubMed ID: 15944423
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
